Speakers: Susan Taylor (University of California, San Diego), Vincent Stoll (Abbott Laboratories), Harren Jhoti (Astex Therapeutics), and Stephen Burley (SGX Pharmaceuticals)Presented by the Biochemical Pharmacology Discussion Group and the American Chemical Society's New York SectionReported by Megan Stephan | Posted August 12, 2009
Overview
Protein kinases are the workhorses of cellular regulation, playing a key role in almost every major pathway in eukaryotic cells, including those that control cell division, cell death, cell growth, and programs of differentiation. These proteins play key regulatory roles in plants and bacteria, including many pathogenic microorganisms. Mutations or overexpression of these proteins is implicated in a wide range of diseases, from cancer to diabetes to neurodegenerative diseases.
An April 28, 2009, meeting of the Academy's Chemical Biology Discussion Group featured four researchers who study kinase structure and function and are working to develop these findings into effective therapeutics. Topics discussed included newly identified, potentially druggable targets in protein kinase A; challenges to kinase-directed drug development, including problems related to toxicity, selectivity, efficacy, and patentability; and advances in the relatively new field of fragment-based drug design, in which small chemical fragments are identified by screening as starting points to build larger, drug-like compounds with favorable physicochemical and clinical properties.
Use the tabs above to find a meeting report and multimedia from this event.
Log in or Join Now to continue